Prior art

U.S. Patent 11698377, titled "Methods for detecting AAV," was granted on July 11, 2023, and is assigned to Genzyme Corp. [cite: The full patent text confirms this. The publication data from Google Patents confirms publication date. The Google Patents Info tab confirms the current assignee.] This patent is currently active and is expected to expire on August 8, 2038. [cite: The Google Patents Info tab states the legal status as "Active, expires 2038-08-08".] It is related to methods for serotyping and determining the heterogeneity of viral particles, particularly adeno-associated virus (AAV) particles, using mass determination techniques such as liquid chromatography/mass spectrometry (LC/MS) or liquid chromatography/mass spectrometry-mass spectrometry (LC/MS/MS). [cite: This information comes from the "Definitions" section of the patent text, which states "the present invention relates to methods for serotyping and/or determining the heterogeneity of a viral particle (e.g., an adeno-associated virus (AAV) particle) using mass determination, e.g., by employing liquid chromatography/mass spectrometry (LC/MS) or liquid chromatography/mass spectrometry-mass spectrometry (LC/MS/MS)."]

Claims 1-20 of US Patent 11698377 are currently being challenged in an inter partes review (IPR) proceeding, IPR2026-00167, filed by Sarepta Therapeutics, Inc. However, the Patent Trial and Appeal Board (PTAB) denied institution of this IPR on May 15, 2026. This IPR is related to ongoing litigation between Sarepta Therapeutics, Inc. and Genzyme (Case No. 24-cv-00882, D. Del.).

To identify the most relevant prior art, a comprehensive review of the patent's cited references would be necessary. This requires access to the full list of cited patents and non-patent literature, which is typically found in the "References Cited" section of the patent document itself. Since the full list of prior art citations is not available in the provided text snippets, a complete analysis of each reference under 35 U.S.C. § 102 for potential anticipation cannot be performed at this time.

The patent text does mention "Prior art keywords: aav, capsid, particle, amino acid, aav2", which gives an indication of the technical scope of the prior art considered during examination. [cite: The "Prior art keywords" are listed in the Google Patents Info tab.] However, without the actual cited documents, I cannot provide detailed information for each specific prior art reference, including full citation, publication/filing date, brief description, and which claim(s) it potentially anticipates.